On ECHEMI
Home > Drugs > Ceftriaxone Sodium for Injection

Ceftriaxone Sodium for Injection

Function and Efficacy

This product is a first-generation cephalosporin with a broad antibacterial spectrum and strong activity against Gram-positive bacteria. Penicillinase-producing and non-penicillinase-producing Staphylococcus aureus, coagulase-negative Staphylococcus, Streptococcus pyogenes, Streptococcus pneumoniae, Group B hemolytic Streptococcus, Streptococcus viridans, Staphylococcus epidermidis, Corynebacterium diphtheriae, and Bacillus anthracis are all quite sensitive to this product. Enterococci, methicillin-resistant Staphylococcus, Listeria, and Nocardia are resistant. Haemophilus influenzae, Neisseria meningitidis, Moraxella catarrhalis, and Neisseria gonorrhoeae are highly sensitive to this product. Some strains of Escherichia coli, Klebsiella, Salmonella, Shigella, and Proteus are moderately sensitive to this product, while most of the other Gram-negative rods are resistant. Gram-positive anaerobic bacteria are sensitive to this product, and Bacteroides fragilis is resistant to this product. This product mainly inhibits the synthesis of bacterial cell walls.

Ingredients

The main ingredient of this product is ceftriaxone sodium.

Name Description Content CAS NO. Manufacturer
Cephalothin sodiumIngredients

This product is a first-generation cephalosporin with a broad antibacterial spectrum and strong activity against Gram-positive bacteria. Penicillinase-producing and non-penicillinase-producing Staphylococcus aureus, coagulase-negative Staphylococcus, Streptococcus pyogenes, Streptococcus pneumoniae, Group B hemolytic Streptococcus, Streptococcus viridans, Staphylococcus epidermidis, Corynebacterium diphtheriae, and Bacillus anthracis are all quite sensitive to this product. Enterococci, methicillin-resistant Staphylococcus, Listeria, and Nocardia are resistant. Haemophilus influenzae, Neisseria meningitidis, Moraxella catarrhalis, and Neisseria gonorrhoeae are highly sensitive to this product. Some strains of Escherichia coli, Klebsiella, Salmonella, Shigella, and Proteus are moderately sensitive to this product, while most of the other Gram-negative rods are resistant. Gram-positive anaerobic bacteria are sensitive to this product, and Bacteroides fragilis is resistant to this product. This product mainly inhibits the synthesis of bacterial cell walls.

More
58-71-9 18

Appearance

This product is white or off-white crystalline powder.

Indication

This product is suitable for respiratory tract infections, soft tissue infections, urinary tract infections, sepsis, etc. caused by penicillin-resistant Staphylococcus aureus (except methicillin-resistant ones) and sensitive Gram-negative bacilli. In severe cases, it can be used in combination with aminoglycoside antibiotics, but caution should be exercised as it may aggravate renal toxicity. This product should not be used in patients with bacterial meningitis.

Usage and Dosage

Adults can be injected intramuscularly or intravenously, 0.5-1g once, once every 6 hours. The daily dose for patients with severe infection can be increased to 6-8g. To prevent postoperative infection, 1-2g can be used 0.5-1 hour before surgery. If the operation time exceeds 3 hours, 1-2g can be given during the operation. According to the condition, it can be given once every 6 hours after surgery, and the drug should be stopped within 24 hours after surgery. For cardiac surgery, artificial joint formation, etc., preventive application can be maintained for 2 days after surgery. The maximum daily dose for adults does not exceed 12g. Children are given 50-100mg/kg of body weight per day, divided into 4 doses. Newborns within 1 week are given 20mg/kg of body weight every 12 hours; those over 1 week old are given 20mg/kg of body weight every 8 hours. Patients with renal impairment should reduce the dose appropriately. When the creatinine clearance rate is less than 10ml/min, 25ml/min, 50ml/min and 80ml/min, the doses given every 6 hours are 0.5g, 1g, 1.5g and 2g respectively. The daily maintenance dose for anuric patients is 1.5g, divided into 3 doses. Hemodialysis and peritoneal dialysis can effectively remove this product. During dialysis, 1g should be given every 6 to 12 hours to maintain effective blood drug concentration. Preparation of intramuscular injection: 1g of this product is dissolved in 4ml sterile water for injection. For intravenous injection, 1g of this product can be dissolved in 10ml sterile water for injection, 5% glucose injection or sodium chloride injection, and the prepared solution is slowly injected within 3 to 5 minutes. For intravenous drip, first dissolve 4g of this product in 20ml sterile water for injection, and then dilute it appropriately. When administered intraperitoneally, generally 60mg of cephalothin sodium is contained in each 1000ml of dialysate. The concentration of cephalothin sodium used to treat peritonitis or abdominal contamination can reach 0.1% to 4%.

Adverse Reactions

1 Local pain is more common, and there may be lumps, tenderness, and increased temperature. The incidence of thrombophlebitis after large-dose or long-term intravenous infusion of ceftriaxone can be as high as 20%. 2 Adverse reactions include rash, eosinophilia, drug fever, serum sickness-like reactions and other allergic reactions. Anaphylactic shock rarely occurs. 3 Cytopenia and hemolytic anemia may occasionally occur. Convulsions and other central nervous system symptoms may occur at doses of 4, especially in patients with renal impairment. 5 Gastrointestinal adverse reactions such as heart palpitations and vomiting are rare. 6 Diarrhea and pseudomembranous enterocolitis caused by Clostridium difficile occur. Encephalopathy may occur at doses of 7.

Precautions

It is contraindicated in patients with a history of cephalosporin allergy and penicillin anaphylactic shock.

Special Population Medication

Precautions during pregnancy and lactation: Use with caution in lactating women.

Drug Interactions

This product is a first-generation cephalosporin with a broad antibacterial spectrum and strong activity against Gram-positive bacteria. Penicillinase-producing and non-penicillinase-producing Staphylococcus aureus, coagulase-negative Staphylococcus, Streptococcus pyogenes, Streptococcus pneumoniae, Group B hemolytic Streptococcus, Streptococcus viridans, Staphylococcus epidermidis, Corynebacterium diphtheriae, and Bacillus anthracis are all quite sensitive to this product. Enterococci, methicillin-resistant Staphylococcus, Listeria, and Nocardia are resistant. Haemophilus influenzae, Neisseria meningitidis, Moraxella catarrhalis, and Neisseria gonorrhoeae are highly sensitive to this product. Some strains of Escherichia coli, Klebsiella, Salmonella, Shigella, and Proteus are moderately sensitive to this product, while most of the other Gram-negative rods are resistant. Gram-positive anaerobic bacteria are sensitive to this product, and Bacteroides fragilis is resistant to this product. This product mainly inhibits the synthesis of bacterial cell walls.

Storage

Keep away from light, sealed and stored in a dry place.

Packaging Specification

1.0g (calculated as C16H17N5O7S2)

Manufacturer

Anhu Welman Pharmaceut Icai Cd.ltd

  • Founded in:

    1992-06-19
  • Address:

    No. 510, Wangjiang West Road, High-tech Zone, Hefei City, Anhui Province
  • Tax NO.:

    913401006103789162
  • Registered Funds:

    $3,041,030
  • Website:

  • Email:

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.